Revolutionising Delivery of Inhaled Therapies
Inspiring is developing a novel medical device for enhanced delivery of inhaled therapies
More than 600 million people worldwide suffer from asthma, chronic obstructive pulmonary disease, cystic fibrosis and other lung conditions, most of whom use some form of inhaled drug delivery device. There is a critical need for new inhalation devices to improve drug delivery and ease of use for people who rely on inhaled therapies
Inspiring is hoping to revolutionise inhaled drug delivery for those who need it most
Inspiring Holdings Pty Ltd was founded in 2019 to address the critical lack of inhalation devices that efficiently deliver drugs to users, regardless of the severity of their disease. We are developing the Universal Spacer System (USS), a spacer to be combined with the following forms of inhalation devices, Metered Dose Inhalers (MDIs), Nebulisers and Dry Powder Inhalers.
An innovative spacer with the aim to improve drug delivery efficiency, ease of use and safety
Inspiring’s USS has been designed with the aim to deliver more drug to the lungs of users, eliminate the need for coordinated breathing, allowing the user to breath with their own breath patterns, and improve safety by eliminating fugitive aerosol, reducing environmental contamination and infection risk.
Winners of the 2023 West Australian Innovator of the Year Wesfarmers Wellbeing Platinum Award
Inspiring was recently awarded the West Australian Innovator of the Year Wesfarmers Wellbeing Platinum Award for the development of our USS.